Journal article
GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)
C Conduit, B Mak, W Qu, JD Lulio, R Burder, M Bressel, T Cusick, HM Dhillon, RDA Lourenço, C Underhill, J Torres, M Crumbaker, F Honeyball, A Linton, R Allen, ID Davis, SJ Clark, LG Horvath, KL Mahon
Therapeutic Advances in Medical Oncology | Published : 2022
Abstract
Objective: To determine the efficacy and safety of intermittent docetaxel chemotherapy guided by circulating methylated glutathione S-transferase Pi-1 (mGSTP1) in men with metastatic castration-resistant prostate cancer (CRPC). Patients and Methods: GUIDE (NCT04918810) is a randomised, two-arm, non-comparative phase-2 trial recruiting 120 patients at six Australian centres. Patients with Prostate Cancer Working Group-3 defined metastatic CRPC who are commencing docetaxel 75 mg/m2 q3w will be pre-screened for detectable mGSTP1 at baseline ± following two cycles of treatment. Those with detectable plasma mGSTP1 at baseline that becomes undetectable after two cycles of chemotherapy will be elig..
View full abstractGrants
Awarded by Cancer Institute NSW
Funding Acknowledgements
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: ANZUP, Chris O'Brien Lifehouse Philanthropic Fund and the Twin Towns Foundation, CINSW TPG (TPG172146), and NHMRC investigator grant (APP1196225).